PMID- 32915203
OWN - NLM
STAT- MEDLINE
DCOM- 20211110
LR  - 20211110
IS  - 1537-6591 (Electronic)
IS  - 1058-4838 (Linking)
VI  - 73
IP  - 9
DP  - 2021 Nov 2
TI  - Higher Completion Rates With Self-administered Once-weekly Isoniazid-rifapentine 
      Versus Daily Rifampin in Adults With Latent Tuberculosis.
PG  - e3459-e3467
LID - 10.1093/cid/ciaa1364 [doi]
AB  - BACKGROUND: Treatment of latent tuberculosis (LTBI) is important for tuberculosis 
      (TB) prevention, and short course rifamycin-based therapies are preferred. 
      Once-weekly isoniazid-rifapentine by self-administered therapy (3HP-SAT) has 
      never been compared with 4 months of daily rifampin (4R). METHODS: Retrospective 
      cohort study of adults >/=18 years of age initiating LTBI treatment with either 
      3HP-SAT or 4R in a United States (US)-based TB clinic between 11 April 2016 and 
      31 December 2018. We evaluated treatment completion through pharmacy fills and 
      reviewed charts for reasons of noncompletion, including adverse events (AEs). The 
      chi 2 test and a log-binomial multivariable model were used to compare treatment 
      completion and AEs. RESULTS: Five hundred sixty individuals (42%) initiated 
      3HP-SAT and 773 (58%) initiated 4R. Median age was 38, 55% were female, and 89% 
      were born outside of the US. Among those aged 18-49 years, treatment completion 
      with 3HP-SAT was 79% compared to 68% with 4R (adjusted risk ratio [aRR], 1.17 
      [95% CI, 1.17-1.27]; P < .0001). Among individuals aged >/=50 years, treatment 
      completion with 3HP-SAT was 87% compared to 64% with 4R (aRR, 1.35 [95% CI, 
      1.19-1.52]; P < .0001). Compared to 4R, there was no difference in risk of AEs in 
      the 18-49 age group (aRR, 0.93 [95% CI, .58-1.48]; P = .75). Reduced risk of AEs 
      was noted among patients aged >/=50 years who received 3HP-SAT (aRR, 0.37 [95% CI, 
      .16-.85]; P = .02). CONCLUSIONS: 3HP-SAT was associated with higher LTBI 
      treatment completion and lower rates of AEs compared to 4R in individuals aged 50 
      and older. Expanding 3HP-SAT as an option for patients with LTBI may enhance TB 
      prevention strategies in the US.
CI  - (c) The Author(s) 2020. Published by Oxford University Press for the Infectious 
      Diseases Society of America. All rights reserved. For permissions, e-mail: 
      journals.permissions@oup.com.
FAU - Haas, Michelle K
AU  - Haas MK
AD  - Denver Health and Hospital Authority, Denver Public Health, Denver, Colorado, 
      USA.
AD  - Division of Infectious Diseases, Department of Medicine, University of 
      Colorado-Denver Anschutz Medical Campus, Aurora, Colorado, USA.
FAU - Aiona, Kaylynn
AU  - Aiona K
AD  - Denver Health and Hospital Authority, Denver Public Health, Denver, Colorado, 
      USA.
FAU - Erlandson, Kristine M
AU  - Erlandson KM
AD  - Division of Infectious Diseases, Department of Medicine, University of 
      Colorado-Denver Anschutz Medical Campus, Aurora, Colorado, USA.
AD  - Division of Geriatric Medicine, Department of Medicine, University of 
      Colorado-Denver Anschutz Medical Campus, Aurora, Colorado, USA.
FAU - Belknap, Robert W
AU  - Belknap RW
AD  - Denver Health and Hospital Authority, Denver Public Health, Denver, Colorado, 
      USA.
AD  - Division of Infectious Diseases, Department of Medicine, University of 
      Colorado-Denver Anschutz Medical Campus, Aurora, Colorado, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Infect Dis
JT  - Clinical infectious diseases : an official publication of the Infectious Diseases 
      Society of America
JID - 9203213
RN  - 0 (Antitubercular Agents)
RN  - V83O1VOZ8L (Isoniazid)
RN  - VJT6J7R4TR (Rifampin)
RN  - XJM390A33U (rifapentine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antitubercular Agents/therapeutic use
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - *Isoniazid/therapeutic use
MH  - *Latent Tuberculosis/drug therapy
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Rifampin/analogs & derivatives/therapeutic use
MH  - United States/epidemiology
OTO - NOTNLM
OT  - isoniazid
OT  - latent
OT  - rifampin
OT  - rifapentine
OT  - tuberculosis
EDAT- 2020/09/12 06:00
MHDA- 2021/11/11 06:00
CRDT- 2020/09/11 12:12
PHST- 2020/05/06 00:00 [received]
PHST- 2020/09/09 00:00 [accepted]
PHST- 2020/09/12 06:00 [pubmed]
PHST- 2021/11/11 06:00 [medline]
PHST- 2020/09/11 12:12 [entrez]
AID - 5904201 [pii]
AID - 10.1093/cid/ciaa1364 [doi]
PST - ppublish
SO  - Clin Infect Dis. 2021 Nov 2;73(9):e3459-e3467. doi: 10.1093/cid/ciaa1364.